MedWatch

What are Genmab's actual plans for drug hope?

Genmab will soon be forced to reveal what the company’s actual plans for cancer drug, daratumumab, are, says an analyst from Jyske Bank. He is holding his breath for three near-term announcements.

Foto: colourbox

On Tuesday morning, Genmab announced that they would be initiating a phase II study with daratumumab for the treatment of myelomatosis. A good - but by no means surprising - announcement, says analyst Frank Hørning Andersen, Jyske Bank. But he calls for information concerning what the Danish biotech and its Belgian-American partner, Janssen, really have planned with daratumumab.

He imagines that daratumumab could show a real potential in treating myelomatosis in earlier stages than the ones the drug is currently being tested for.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier